Clinical Trial Update: Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating quality of life in chronic or high-frequency episodic migraine patients treated with erenumab has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• erenumab (erenumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Migraine | Phase 3 | Status: WITHDRAWN